Abstract
Introduction

Hepatocellular carcinoma (HCC) is currently a very common malignancy and its incidence is increasing, both in the far eastern Asian countries and in the US. Particularly, in Japan, persistent hepatitis C virus (HCV) infection is a major risk factor for the development of HCC, which is quite different from other Asian countries. Therefore, we have to recognize that HCV-associated chronic liver diseases are an extremely risky condition considering the complication of HCC.
However, the molecular mechanism of hepatocarcinogenesis in HCV infection remains unclear. Because, HCV belongs to RNA virus, and is not integrated into host hepatocyte DNA which causes the mutation. Whereas, concerning HBV, it is well known that integrated HBV genome into hepatic DNA may play an important role in hepatocarcinogenesis (1) (2) (3) .
As for the mortality rate among the patients of HCC, it reached to over 30 (13) . This is quite in contrast to the countries where are the high incidence of HBV positive HCC patients are younger age.
Establishment of high risk group for HCC
According to Tsukuma (14) , the following factors are im- (Fig. 1) . Application of this algorism will be useful for early detection of HCC.
Therapy
Surgical resection should be the first choice in the therapy of HCC as well as in other solid cancers. However, HCC develops usually in the cirrhotic liver accompanied with se-
vere liver damage and therefore surgical treatment is so limited. The study group mentioned above also proposed an algorism on the treatment of HCC (Fig. 2) (25) . Although it is known whether iron radical is very toxic, there is also increasing evidence that ROS produced by infection of HCV may play an important role in hepatocarcinogenesis (9, 10) . Our studies showed clearly that attachment of HCV core to hepatic mitochondria disrupts electron transport and accelerates ROS production (9) . Consequently, anti-oxidant may lead to the decrease of risk of HCC (26, 27) . On a different line of agents than anti-viral and anti-oxidative agents, the following two agents developed in Japan have been noted from the view points of chemoprevention of HCC: one is acyclic retinoid (28, 29) , and the other is vitamin K2 (30) 
